Celon Pharma SA Tangible Net Worth Ratio
Celon Pharma SA tangible net worth ratio. Celon Pharma SA (CLN) has a Tangible Net Worth Ratio of 96.0% as of March 2026. This metric is calculated by deducting intangible assets (zł21.33 Million) from net assets (zł528.78 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. Also explore net asset momentum of Celon Pharma SA to track the company's year-over-year net asset growth rate.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of Celon Pharma SA (2012–2025)
Tangible net worth ratio of Celon Pharma SA from 2012 to 2025. This chart shows how Celon Pharma SA's Tangible Net Worth Ratio has changed across 14 annual periods from 2012 to 2025. As of March 2026, the ratio stands at 96.0%, reflecting net assets of zł528.78 Million with intangible assets of zł21.33 Million PLN. Check Celon Pharma SA (CLN) strategic investment index to assess the company's strategic physical and investment asset allocation.
Celon Pharma SA Tangible Net Worth Ratio by Year (2012–2025)
Celon Pharma SA tangible net worth ratio by year from 2012 to 2025. The table below presents the year-by-year Tangible Net Worth Ratio for Celon Pharma SA from 2012 to 2025, covering 14 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see CLN company net worth.
| Year | Tangible NW Ratio | Net Assets (PLN) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 95.9% | zł382.99 Million | zł15.69 Million | zł457.46 Million | ▼ -2.3 pp |
| 2024 | 98.2% | zł445.21 Million | zł8.15 Million | zł543.79 Million | ▲ +1.5 pp |
| 2023 | 96.6% | zł445.56 Million | zł14.97 Million | zł569.31 Million | ▲ +2.5 pp |
| 2022 | 94.1% | zł479.65 Million | zł28.12 Million | zł608.93 Million | ▼ -0.6 pp |
| 2021 | 94.7% | zł554.00 Million | zł29.17 Million | zł707.14 Million | ▲ +4.2 pp |
| 2020 | 90.5% | zł434.67 Million | zł41.09 Million | zł703.64 Million | ▼ -8.1 pp |
| 2019 | 98.6% | zł445.04 Million | zł6.16 Million | zł591.35 Million | ▲ +0.3 pp |
| 2018 | 98.3% | zł448.73 Million | zł7.41 Million | zł563.67 Million | ▼ -1.1 pp |
| 2017 | 99.4% | zł439.85 Million | zł2.64 Million | zł525.05 Million | ▲ +0.2 pp |
| 2016 | 99.2% | zł402.50 Million | zł3.36 Million | zł464.32 Million | ▲ +2.1 pp |
| 2015 | 97.1% | zł100.82 Million | zł2.97 Million | zł168.29 Million | ▼ -1.6 pp |
| 2014 | 98.7% | zł69.62 Million | zł904.73K | zł105.44 Million | ▼ -0.5 pp |
| 2013 | 99.2% | zł52.20 Million | zł407.81K | zł82.59 Million | ▲ +0.1 pp |
| 2012 | 99.1% | zł55.57 Million | zł479.61K | zł69.80 Million | — |